世界のヒトマイクロバイオーム治療市場2020-2024

◆英語タイトル:Global Human Microbiome Therapeutics Market 2020-2024
◆商品コード:IRTNTR43730
◆発行会社(リサーチ会社):Technavio
◆発行日:2020年5月27日
◆ページ数:約120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:北米、ヨーロッパ、アジア太平洋、その他
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥265,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥318,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥424,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートではヒトマイクロバイオーム治療の世界市場について調査・分析し、エグゼクティブサマリー、市場状況、市場規模、ファイブフォース分析、用途別(胃腸疾患、免疫学的症状、その他)分析、顧客状況、地域別状況、企業状況、企業分析などを総合的、多面的に調査・分析しました。
・エグゼクティブサマリー
・市場状況
・市場規模
・ファイブフォース分析
・ヒトマイクロバイオーム治療の世界市場:用途別(胃腸疾患、免疫学的症状、その他)
・顧客状況
・地域別状況
・企業状況
・企業分析
【レポートの概要】

Global Human Microbiome Therapeutics Market 2020-2024

Technavio has been monitoring the human microbiome therapeutics market and it is poised to grow by USD 276.93 mn during 2020-2024 progressing at a CAGR of 15% during the forecast period. Our reports on human microbiome therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the growing prevalence of chronic diseases and robust pipeline. In addition, growing prevalence of chronic diseases is anticipated to boost the growth of the market as well.

The human microbiome therapeutics market analysis includes application segment and geographic landscapes
Technavio’s human microbiome therapeutics market is segmented as below:
By Application
• Gastrointestinal disorders
• Immunological conditions
• Others

By Geographic Landscapes
• North America
• Europe
• APAC
• ROW

This study identifies the side effects of existing treatment as one of the prime reasons driving the human microbiome therapeutics market growth during the next few years.
“Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our human microbiome therapeutics market covers the following areas:
• Human microbiome therapeutics market sizing
• Human microbiome therapeutics market forecast
• Human microbiome therapeutics market industry analysis”

Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading human microbiome therapeutics market vendors that include Bristol-Myers Squibb Co., Dow Inc., ENTEROME SA, Ferring Pharmaceuticals AS, Johnson & Johnson, Kaleido Biosciences Inc., PureTech Health Plc, Second Genome Therapeutics, Seres Therapeutics Inc., and Takeda Pharmaceutical Co. Ltd.. Also, the human microbiome therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit – https://www.technavio.com/report/global-human-microbiome-therapeutics-market-industry-analysis

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

【レポートの目次】

• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2019
o Market outlook: Forecast for 2019 – 2024
• Five Forces Analysis
o Five forces summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Application
o Market segments
o Comparison by Application
o Gastrointestinal disorders – Market size and forecast 2019-2024
o Immunological conditions – Market size and forecast 2019-2024
o Others – Market size and forecast 2019-2024
o Market opportunity by application
• Customer landscape
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America – Market size and forecast 2019-2024
o Europe – Market size and forecast 2019-2024
o APAC – Market size and forecast 2019-2024
o ROW – Market size and forecast 2019-2024
o Key leading countries
o Market opportunity by geography
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Vendor landscape
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o Bristol-Myers Squibb Co.
o Dow Inc.
o ENTEROME SA
o Ferring Pharmaceuticals AS
o Johnson & Johnson
o Kaleido Biosciences Inc.
o PureTech Health Plc
o Second Genome Therapeutics
o Seres Therapeutics Inc.
o Takeda Pharmaceutical Co. Ltd.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations

Exhibit
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Parent market
• 9: Market characteristics
• 10: Offerings of vendors included in the market definition
• 11: Market segments
• 12: Global – Market size and forecast 2019 – 2024 ($ million)
• 13: Global market: Year-over-year growth 2019 – 2024 (%)
• 14: Five forces analysis 2019 & 2024
• 15: Bargaining power of buyers
• 16: Bargaining power of suppliers
• 17: Threat of new entrants
• 18: Threat of substitutes
• 19: Threat of rivalry
• 20: Market condition – Five forces 2019
• 21: Application – Market share 2019-2024 (%)
• 22: Comparison by Application
• 23: Gastrointestinal disorders – Market size and forecast 2019-2024 ($ million)
• 24: Gastrointestinal disorders – Year-over-year growth 2019-2024 (%)
• 25: Immunological conditions – Market size and forecast 2019-2024 ($ million)
• 26: Immunological conditions – Year-over-year growth 2019-2024 (%)
• 27: Others – Market size and forecast 2019-2024 ($ million)
• 28: Others – Year-over-year growth 2019-2024 (%)
• 29: Market opportunity by Application
• 30: Customer landscape
• 31: Market share by geography 2019-2024 (%)
• 32: Geographic comparison
• 33: North America – Market size and forecast 2019-2024 ($ million)
• 34: North America – Year-over-year growth 2019-2024 (%)
• 35: Europe – Market size and forecast 2019-2024 ($ million)
• 36: Europe – Year-over-year growth 2019-2024 (%)
• 37: APAC – Market size and forecast 2019-2024 ($ million)
• 38: APAC – Year-over-year growth 2019-2024 (%)
• 39: ROW – Market size and forecast 2019-2024 ($ million)
• 40: ROW – Year-over-year growth 2019-2024 (%)
• 41: Key leading countries
• 42: Market opportunity by geography ($ million)
• 43: Impact of drivers and challenges
• 44: Vendor landscape
• 45: Landscape disruption
• 46: Industry risks
• 47: Vendors covered
• 48: Market positioning of vendors
• 49: Bristol-Myers Squibb Co. – Overview
• 50: Bristol-Myers Squibb Co. – Business segments
• 51: Bristol-Myers Squibb Co. – Key offerings
• 52: Bristol-Myers Squibb Co. – Key customers
• 53: Bristol-Myers Squibb Co. – Segment focus
• 54: Dow Inc. – Overview
• 55: Dow Inc. – Business segments
• 56: Dow Inc. – Key offerings
• 57: Dow Inc. – Key customers
• 58: Dow Inc. – Segment focus
• 59: ENTEROME SA – Overview
• 60: ENTEROME SA – Product and service
• 61: ENTEROME SA – Key offerings
• 62: ENTEROME SA – Key customers
• 63: ENTEROME SA – Segment focus
• 64: Ferring Pharmaceuticals AS – Overview
• 65: Ferring Pharmaceuticals AS – Product and service
• 66: Ferring Pharmaceuticals AS – Key offerings
• 67: Ferring Pharmaceuticals AS – Key customers
• 68: Ferring Pharmaceuticals AS – Segment focus
• 69: Johnson & Johnson – Overview
• 70: Johnson & Johnson – Business segments
• 71: Johnson & Johnson – Key offerings
• 72: Johnson & Johnson – Key customers
• 73: Johnson & Johnson – Segment focus
• 74: Kaleido Biosciences Inc. – Overview
• 75: Kaleido Biosciences Inc. – Product and service
• 76: Kaleido Biosciences Inc. – Key offerings
• 77: Kaleido Biosciences Inc. – Key customers
• 78: Kaleido Biosciences Inc. – Segment focus
• 79: PureTech Health Plc – Overview
• 80: PureTech Health Plc – Business segments
• 81: PureTech Health Plc – Key offerings
• 82: PureTech Health Plc – Key customers
• 83: PureTech Health Plc – Segment focus
• 84: Second Genome Therapeutics – Overview
• 85: Second Genome Therapeutics – Product and service
• 86: Second Genome Therapeutics – Key offerings
• 87: Second Genome Therapeutics – Key customers
• 88: Second Genome Therapeutics – Segment focus
• 89: Seres Therapeutics Inc. – Overview
• 90: Seres Therapeutics Inc. – Product and service
• 91: Seres Therapeutics Inc. – Key offerings
• 92: Seres Therapeutics Inc. – Key customers
• 93: Seres Therapeutics Inc. – Segment focus
• 94: Takeda Pharmaceutical Co. Ltd. – Overview
• 95: Takeda Pharmaceutical Co. Ltd. – Product and service
• 96: Takeda Pharmaceutical Co. Ltd. – Key offerings
• 97: Takeda Pharmaceutical Co. Ltd. – Key customers
• 98: Takeda Pharmaceutical Co. Ltd. – Segment focus
• 99: Currency conversion rates for US$
• 100: Research Methodology
• 101: Validation techniques employed for market sizing
• 102: Information sources
• 103: List of abbreviations



【掲載企業】

Bristol-Myers Squibb Co., Dow Inc., ENTEROME SA, Ferring Pharmaceuticals AS, Johnson & Johnson, Kaleido Biosciences Inc., PureTech Health Plc, Second Genome Therapeutics, Seres Therapeutics Inc., Takeda Pharmaceutical Co. Ltd.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界のヒトマイクロバイオーム治療市場2020-2024]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆